New drug used to treat breast cancer heralded as 'quite groundbreaking'
By Catholic Online (NEWS CONSORTIUM)
4/6/2014 (4 years ago)
Catholic Online (https://www.catholic.org)
An important treatment option in the fight against breast cancer may be waiting in the wings. Researchers say a new type of drug could help prevent advanced breast cancer from worsening. The potential is great for breast cancer patients, and makes for a potential blockbuster product for Pfizer.
While Pfizer remains in the lead to bring this new class of drugs to market, Novartis has begun late-stage testing of its own CDK 4/6 inhibitor.
LOS ANGELES, CA (Catholic Online) - Said drug cut in half the risk that cancer would worsen, or progress, researchers said. The median time before the disease progressed or the women died was 20.2 months for those who received the drug, compared with 10.2 months for the control group.
"The magnitude of benefit we are seeing is not something commonly seen in cancer medicine studies," Dr. Richard S. Finn, a principal investigator in the study, says. Finn, an oncologist at the University of California, Los Angeles, called the results "quite groundbreaking."
No child need ever go to bed hungry -- Learn how you can help!
Known as palbociclib, the drug also appeared to prolong survival but not by a statistically significant amount. Those who received the drug lived a median of 37.5 months in contrast with 33.3 months for those in the control group.
The results from the Phase 2, or mid-stage, study were presented here at the annual meeting of the American Association for Cancer Research. Palbociclib is considered a jewel in Pfizer's product pipeline, with analysts predicting annual sales of billions of dollars. Amgen is entitled to an eight percent royalty on sales of the drug.
Some investors may have been letdown due to the drug, partly because they were not quite as good as interim results presented about halfway through the trial. At that point, the difference in median progression-free survival was 26.1 months for palbociclib versus 7.5 months for the control group.
Finn stresses that a statistically significant survival benefit should not have been expected at this point because only 61 of the 165 patients in the trial had died. Patients can use other drugs after leaving the trial, which can dilute any effect of palbociclib.
Palbociclib slows the proliferation of cancer cells by inhibiting the activity of two related enzymes involved in cell division; cyclin-dependent kinases 4 and 6.
While Pfizer remains in the lead to bring this new class of drugs to market, Novartis has begun late-stage testing of its own CDK 4/6 inhibitor. While breast cancer is the initial focus, the drugs are being tested for other cancers.
Breast cancer specialists not involved in the study were encouraged -- but expressed caution. "These results are strikingly positive and with a large potential impact to patients," Dr. José Baselga said in a speech at the conference discussing the results.
Baselga, the physician in chief at the Memorial Sloan-Kettering Cancer Center, also said the results might have been biased because the study investigators, who determined whether tumors had progressed, knew which patients were getting palbociclib.
Dr. Eric P. Winer, chief of women's cancers at the Dana-Farber Cancer Institute in Boston, says larger studies were still needed.
"This is a small Phase 2 trial - not tiny, but not the kind of study that would typically lead to a change in practice," he said.
Copyright 2018 - Distributed by THE CALIFORNIA NETWORK
Pope Francis Prayer Intentions for APRIL 2018
For those who have Responsibility in Economic Matters. That economists may have the courage to reject any economy of exclusion and know how to open new paths.
A clean needle exchange program that distributes condoms is hosted in the parking lot of an Ohio Catholic hospital, and one Catholic ... continue reading
Just when you thought you made it through flu season unharmed, the Centers for Disease Control (CDC) announces the dangers of a second wave ... continue reading
The Mexican Senate has approved a measure protecting the conscientious objections of medical personnel who hold moral or ethical objections ... continue reading
A new study involving patients in four countries has discovered that stem cells may stop multiple sclerosis and can even relieve symptoms. ... continue reading
Doctors from the World Health Organization have added a new disease to their list of potential pandemics, Disease X. The illness is ... continue reading
by Catholic Online
- Pope Francis tells priests to 'Be like Jesus the Good Shepherd'
- St. Fidelis of Sigmaringen: Saint of the Day for Tuesday, April 24, 2018
- Every Earth Day, Remember Our Place in Creation HD Video
- Earth Day 2018: We are stewards of Creation, and we must act like it
- The Christian Duty: A mission of leading others to Jesus
- Two Leaves Tea at Catholic Online Shopping HD Video
- Daily Readings for Tuesday, April 24, 2018
- st james
- st joan of arc
- advent prayers
- St Joseph
- ten commandments
- Pope Francis
- saint agnes
- St Anthony
- 10 commandments
- mary magdalene
- Patron saints
- st bernadette
- pope francis
- St. John
- holy spirit
- morning prayer
- Saint Elizabeth
- St. Augustine
- Saint Anne
- st agnes
- saint monica
- saint catherine
- Beautiful Divine Mercy One Decade Rosary at Catholic Online Shopping HD
- St. Gemma Galgani HD
- Daily Reading for Wednesday, April 25th, 2018 HD
- Daily Reading for Tuesday, April 24th, 2018 HD
Learn about Catholic world
Inform - Inspire - Ignite
Catholic Online Saints
Your saints explained
Catholic Online Prayers
Prayers for every need
Catholic Online Bible
Complete bible online
Catholic Online News
Your news Catholic eye
Today's bible reading
Products and services we offer
Catholic Online Shopping
Catholic medals, gifts & books
The California Network
Inspiring streaming service
Learn the Catholic way
Teacher lesson plans & resources
Support Free Education
Tax deductible support Free education